YLL545

YLL545 is a type of vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor. YLL545 can inhibit VEGF-induced phosphorylation of VEGFR2 and the activation of downstream signaling factors (like phosphorylated STAT3 and phosphorylated ERK1/2) in human umbilical vein endothelial cells (HUVEC) . YLL545 can suppress the proliferation, migration, invasion, and angiogenesis of HUVEC. YLL545 can induce apoptosis in breast cancer mice and inhibit tumor growth[1].

Product Specifications

CAS Number

[1423126-69-5]

UNSPSC

12352005

Target

Apoptosis; ERK; STAT; VEGFR

Type

Reference compound

Related Pathways

Apoptosis; JAK/STAT Signaling; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/yll545.html

Smiles

O=C(NC1=CC=CC(C(F)(F)F)=C1)NC2=CC=C(OC3=C4C(NN=C4)=NC=N3)C=C2

Molecular Formula

C19H13F3N6O2

Molecular Weight

414.34

References & Citations

[1]Zhang J, et al. The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer. Oncotarget. 2016 Jul 5;7 (27) :41067-41080.